文献速递肿瘤 PET/CT

食管鳞状细胞癌患者[68Ga]Ga-FAPI PET/CT计算成纤维细胞活化蛋白表达肿瘤体积的预后价值

Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-12

本研究基于前瞻性母研究(NCT04416165)的回顾性分析,纳入2019年12月至2021年3月45例局部晚期食管鳞状细胞癌患者,计算原发灶SUVmax、GTV和TL-FAPI。34例符合标准,中位随访24个月(16-29个月)。多因素分析显示GTVFAPI是无进展生存(HR 5.76,95%CI 2.13-15.57,P=0.001)和总生存(HR 4.96,95%CI 2.55-18.79,P=0.001)的独立预后因素。

要点

  • T4期患者SUVmax-FAPI、GTVFAPI和TL-FAPI均显著高于T2/T3期患者(均P<0.01)。
  • GTVFAPI是无进展生存(HR 5.76,95%CI 2.13-15.57,P=0.001)和总生存(HR 4.96,95%CI 2.55-18.79,P=0.001)的独立预后因素。
  • [68Ga]Ga-FAPI PET/CT可能对接受根治性放化疗的食管鳞状细胞癌患者具有预后价值。

核心结论

  • 本先导研究提示[68Ga]Ga-FAPI PET/CT可能对接受根治性放化疗的食管鳞状细胞癌患者具有预后价值。
  • GTVFAPI是无进展生存和总生存的独立预后因素。
  • 可能通过指导治疗前方案调整辅助个体化患者管理。

研究设计与样本

  • 基于前瞻性母研究(NCT04416165)的回顾性分析。
  • 纳入2019年12月至2021年3月45例接受[68Ga]Ga-FAPI PET/CT的局部晚期食管鳞状细胞癌患者。
  • 从PET/CT图像计算原发灶SUVmax、GTV和TL-FAPI。
  • 采用Student t检验或Mann-Whitney U检验比较非配对参数,配对t检验或Wilcoxon配对符号秩检验比较配对参数。
  • 采用Kaplan-Meier曲线计算无进展生存率和总生存率,Cox回归分析确定预后因素。

主要发现

  • 45例中34例符合标准,中位随访24个月(16-29个月)。
  • T4期患者SUVmax-FAPI、GTVFAPI和TL-FAPI均显著高于T2/T3期患者(均P<0.01)。
  • 单因素Cox回归分析中,T分期、N分期、GTVFAPI和TL-FAPI与无进展生存相关;T分期、GTVFAPI和TL-FAPI与总生存相关。
  • 多因素分析中,GTVFAPI是无进展生存的独立预后因素(HR 5.76,95%CI 2.13-15.57,P=0.001)。
  • 多因素分析中,GTVFAPI是总生存的独立预后因素(HR 4.96,95%CI 2.55-18.79,P=0.001)。

关键数值与推荐

  • SUVmax-FAPI、GTVFAPI和TL-FAPI在T4期患者中显著高于T2/T3期患者(均P<0.01)。
  • GTVFAPI对无进展生存的HR为5.76(95%CI 2.13-15.57,P=0.001)。
  • GTVFAPI对总生存的HR为4.96(95%CI 2.55-18.79,P=0.001)。

临床怎么用

  • 本先导研究提示[68Ga]Ga-FAPI PET/CT可能通过指导治疗前方案调整辅助个体化患者管理。
  • 需开展更大样本量、更长观察期的前瞻性研究。

局限性

  • 本先导研究样本量小(34例符合标准)。
  • 本研究为回顾性分析。
  • 随访时间较短(中位24个月,范围16-29个月)。
  • 需开展更大样本量、更长观察期的前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to investigate the prognostic value of semiquantitative parameters derived from [68 Ga]Ga-fibroblast activation protein inhibitor (FAPI) PET/CT for patients with esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy. METHODS: We conducted a retrospective analysis on patients from a prospective parent study (NCT04416165). A total of 45 patients with locally advanced ESCC who underwent [68 Ga]Ga-FAPI from December 2019 to March 2021 were included. The maximum standard uptake value (SUVmax), gross tumor volume (GTV), and total lesion-FAPI (TL-FAPI) of the primary tumor were calculated from the corresponding PET/CT image. Unpaired parameters were compared using Student's t test or the Mann-Whitney U test. Paired parameters were compared using the paired t test or the Wilcoxon matched-pairs signed-rank test. Kaplan-Meier curves were generated to calculate progression-free survival (PFS) and overall survival (OS) rates, and Cox regression analysis was performed to determine which PET/CT parameters were prognostic factors for PFS and/or OS. RESULTS: Thirty-four of the 45 patients met the criteria, and the median follow-up time was 24 months (16-29 months). SUVmax-FAPI, GTVFAPI, and TL-FAPI in patients with stage T4 tumors were significantly higher than those in patients with stage T2/T3 tumors (all P < 0.01). In the univariate Cox regression analysis, T stage, N stage, GTVFAPI, and TL-FAPI were associated with PFS, and T stage, GTVFAPI, and TL-FAPI were associated with OS. Upon multivariable analysis, GTVFAPI was an independent prognostic factor for both PFS (hazard ratio (HR), 5.76; 95% confidence interval (CI), 2.13-15.57, P = 0.001) and OS (HR, 4.96; 95% CI, 2.55-18.79, P = 0.001). CONCLUSION: This pilot study revealed that [68 Ga]Ga-FAPI PET/CT may have prognostic value for patients with ESCC treated with definitive chemoradiotherapy. It may aid in personalized patient management by steering treatment modifications before therapy. Prospective studies with larger samples and longer observation periods are needed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhao L, Pang Y, Chen S, et al. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 36222855. doi:10.1007/s00259-022-05989-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。